How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

501 results for

Superficial Thrombophlebitis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. A multicenter, randomized, placebo-controlled trial of endovenous thermal ablation with or without polidocanol endovenous microfoam treatment in patients with great saphenous vein incompetence and visible varicosities. (PubMed)

trended similarly. Polidocanol endovenous microfoam provided improvements in clinically meaningful change in patient-assessed and physician-assessed appearance ( p < 0.05), need for additional treatment ( p < 0.05), saphenofemoral junction reflux elimination, symptoms, and QOL. In PEM recipients, the most frequent adverse event was superficial thrombophlebitis (35.4%) Conclusions Endovenous thermal ablation + PEM significantly improved physician-assessed appearance at Week 8, increased the proportion (...) A multicenter, randomized, placebo-controlled, blinded study was conducted in patients with great saphenous vein incompetence and symptomatic and visible superficial venous disease. Co-primary endpoints were physician-assessed and patient-assessed appearance change from Baseline to Week 8. Results A total of 117 patients received treatment (38 placebo, 39 PEM 0.5%, 40 PEM 1%). Physician-rated vein appearance at Week 8 was significantly better with PEM ( p = 0.001 vs. placebo); patient-assessed appearance

Full Text available with Trip Pro

2016 Phlebology / Venous Forum of the Royal Society of Medicine Controlled trial quality: uncertain

162. Prevention and management of venous thromboembolism

of thromboprophylaxis 34 9 d iagnosis of venous thromboembolism 36 9.1 Diagnosis of acute venous thromboembolism 36 9.2 Diagnostic algorithms 36 9.3 Confirmation of clinically suspected deep vein thrombosis 38 9.4 Confirmation of clinically suspected pulmonary embolism 38 10 Preliminary assessment 40 10.1 Clinical and laboratory investigations 40 11 initial management of venous thromboembolism 42 11.1 Pulmonary embolism 42 11.2 Lower limb DVT 44 11.3 Superficial thrombophlebitis 45 11.4 Upper extremity DVT 46 11.5 (...) for antithrombotic therapy. a t esting for inherited forms of thrombophilia (antithrombin, protein C, protein S deficiency and factor V Leiden and prothrombin G20210A) does not influence initial management of venous thromboembolism and should not be performed routinely. C u nselective screening for cancer in patients with deep vein thrombosis or pulmonary embolism is not indicated. 2.7 initial management of venous thromboembolism 2.7.1 SUPERFICIAL THROMBOPHLEBITIS d Patients with clinical signs of superficial

2010 SIGN

164. Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer

[ ]. The bacterial pathogens that cause most bloodstream infections in the setting of neutropenia are listed in . Fungi are rarely identified as the cause of first fever early in the course of neutropenia; rather, they are encountered after the first week of prolonged neutropenia and empirical antibiotic therapy. Yeasts, primarily Candida species, may cause superficial infections of mucosal surfaces (eg, thrush); chemotherapy-induced mucositis, in turn, may disrupt this barrier [ ], allowing Candida to enter

Full Text available with Trip Pro

2010 Infectious Diseases Society of America

165. Lake Washington Vascular VenaSealâ„¢ Post-Market Evaluation (WAVES)

, or active acute superficial thrombophlebitis, or thrombophlebitis migrans; Previous treatment such as laser or radiofrequency ablation of venous disease in targeted vein segment; Known hypercoagulable disorder; Pregnant or breast feeding at enrollment; Known sensitivity to cyanoacrylate adhesives; Venous treatment in the contralateral limb within the last 30 days, or who require contralateral treatment within three months; Planned to undergo additional ipsilateral treatments on the same leg within 3 (...) ): Lake Washington Vascular Study Details Study Description Go to Brief Summary: The VenaSeal Closure system offers an outpatient treatment option for the permanent closure of lower extremity superficial truncal veins, such as the great saphenous vein (GSV), through endovascular embolization with coaptation. VenaSeal is intended for use in adults with clinically symptomatic venous reflux as diagnosed by duplex ultrasound (DUS). Condition or disease Intervention/treatment Phase Venous Reflux Device: SP

2015 Clinical Trials

166. Laser Ablation Versus Mechanochemical Ablation Trial

by (Responsible Party): Daniel Carradice, University of Hull Study Details Study Description Go to Brief Summary: A randomised clinical trial comparing endovenous laser ablation and mechanochemical ablation (ClariVein®) in the management of superficial venous insufficiency. Condition or disease Intervention/treatment Phase Varicose Veins Device: Endovenous Laser Ablation Device: Mechanochemical Ablation Drug: Lidocaine with 1:200,000 epinephrine solution Drug: Sodium Bicarbonate Drug: Sodium Tetradecyl (...) better results. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 140 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomised Clinical Trial Comparing Endovenous Laser Ablation and Mechanochemical Ablation (ClariVein®) in the Management of Superficial Venous Insufficiency Study Start Date : June 2015 Estimated Primary Completion

2015 Clinical Trials

167. Clinical Study of Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis

, Beijing. Recruitment status was: Recruiting First Posted : July 13, 2016 Last Update Posted : July 13, 2016 Sponsor: Xuanwu Hospital, Beijing Information provided by (Responsible Party): Xuanwu Hospital, Beijing Study Details Study Description Go to Brief Summary: This is a randomized study comparing Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis (superficial femoral or popliteal artery). Condition or disease Intervention/treatment Phase Atherosclerosis (...) In-stent Arterial Restenosis Device: plaque excision system Device: stent Device: Balloon Not Applicable Detailed Description: This is a randomized study comparing Stent Versus Direct Atherectomy Versus Angioplasty to Treat Lower Limb In-stent Restenosis (superficial femoral or popliteal artery). Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 120 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking

2015 Clinical Trials

168. The Prevention of Pain Associated With Rocuronium Injection

18- 70 years of ASA (American Society of Anesthesiologists) physical status I- II who were to undergo various elective operations. None of the patients was premedicated before the operation. The patients were monitored with three derivation electrocardiogram, non- invasive arterial pressure, and pulse oximeter. A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated Ringer's solution was infused at 100 ml/h for five minutes (...) With Acetaminophen and Lidocaine Study Start Date : May 2014 Actual Primary Completion Date : September 2014 Actual Study Completion Date : October 2014 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment Placebo Comparator: Placebo (Group I) For pretreatment the patients were administered IV 5ml normal saline. A 20-gauge catheter was inserted into a superficial vein on the dorsum of the patient's non- dominant hand. The lactated

2015 Clinical Trials

169. A Multicenter Study to Evaluate the Efficacy and Safety of Cinryze® for the Treatment of Acute Antibody-mediated Rejection in Participants With Kidney Transplant

myocardial infarction (MI) within the past 6 months and/or at the time of screening are treated with anticoagulants and/or antiplatelet agents (excluding aspirin) for a previous myocardial infarction. Have a history of: abnormal bleeding, clotting events or disorders (excluding a history of clotted hemodialysis access or superficial thrombophlebitis in the absence of medically confirmed coagulopathy), any coagulopathy (documented or clinically suspected) For example, participants should be excluded

2015 Clinical Trials

170. The Vaginal Health Trial

/No). pH [ Time Frame: Week 12 ] Objective measures of genitourinary atrophy: pH (<5 or >5) at week 12 Vaginal Maturation Index [ Time Frame: Week 12 ] Objective Measures of Genitourinary Atrophy: Vaginal Maturation Index (VMI) described by % parabasal, intermediate, and superficial cells (≤ 5% or >5% superficial cells) at week 12 Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor (...) , attempting pregnancy or breast feeding Current acute vaginal infection (as indicated by wet mount at V1) Pelvic or vaginal surgery in prior 60 days Antibiotic use in the past 30 days Women under age 55 with endometrial ablation Women under age 55 with hysterectomy and at least one ovary Current cancer treatment (exception basal or squamous skin cell cancers) Current or past thromboembolic disease (pulmonary embolus or deep vein thrombosis, not including thrombophlebitis), myocardial infarction or stroke

2015 Clinical Trials

171. Clinical Study of Stent Versus Direct Atherectomy to Treat Lower Limb Ischemia

Party): Xuanwu Hospital, Beijing Study Details Study Description Go to Brief Summary: This is a randomized study comparing stent and plaque excision systems in treatment of lower limb (superficial femoral or popliteal artery) ischemia. Condition or disease Intervention/treatment Phase Atherosclerosis Ischemia Device: plaque excision system Device: Stent Not Applicable Detailed Description: This is a randomized study comparing stent and plaque excision systems in treatment of diabetic lower limb (...) (superficial femoral or popliteal artery) ischemia. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 120 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment Study Start Date : January 2014 Actual Primary Completion Date : March 2016 Actual Study Completion Date : April 2016 Arms and Interventions Go to Arm Intervention/treatment Active Comparator

2015 Clinical Trials

172. Evaluation of the Safety of Compressive Socks to Treat Venous Insufficiency in Patients With Peripheral Arterial Disease

from the ankle to the knee. Progressive compressive stockings were developed to have a maximal pressure at the calf. This concept is based on the calf pump role in the venous return. Patients with PAD (Peripheral Arterial Disease) often suffer from venous insufficiency. But elastic compression stockings are strictly contraindicated for patients with PAD because highest pressures on ankle could slow down the superficial microcirculation. On patients with PAD and venous insufficiency, the progressive (...) coerulea dolens Septic thrombophlebitis Severe coronary artery disease Oozing and infectious skin diseases, skin ulcers Known hypersensitivity to components of the study compressive stockings Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02431819

2015 Clinical Trials

173. Parenteral Antibiotics Compared to Combination of Oral and Parenteral Antibiotics in Colorectal Surgery Prophylaxis

] Superficial, deep, body-cavity This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently Secondary Outcome Measures : Hospital stay [ Time Frame: Participants will be followed for the duration of hospital stay, an expected average of 7 days ] Hospital stay since colorectal surgery is done Direct Adverse Drug Reactions [ Time Frame: 24 hours since the drug is taken ] Allergic reactions Intolerance •This morbidity problems are reported independently (...) independently as a YES/NO variable Vascular Complications [ Time Frame: 30 days after surgery ] Deep venous thrombosis, phlebitis, thrombophlebitis, ... This is a Clinical measure supported by more specific test if necessary . This morbidity problems are reported independently as a YES/NO variable Gastrointestinal complications [ Time Frame: 30 days after surgery ] Liver failure, gastrointestinal bleeding, severe malnutrition, ... This is a Clinical measure supported by blood test and further test

2015 Clinical Trials

174. Efficacy and Safety of Esarin Gel in Chronic Venous Insufficiency and Varicose Veins

Information provided by (Responsible Party): Ten Sun Pharma Company Limited Study Details Study Description Go to Brief Summary: Evaluation efficacy and safety of Esarin Gel in subjects with chronic venous insufficiency or varicose veins combine superficial vein thrombophlebitis. Condition or disease Intervention/treatment Phase Chronic Venous Insufficiency Varicose Vein Superficial Vein Thrombophlebitis Drug: Esarin Gel Phase 4 Detailed Description: Open-label,non-controlled study design with three (...) visits (pre-treatment/baseline, treatment day 14 and day 28). Administered Esarin Gel twice daily for 28 days in subjects with chronic venous insufficiency rated between CEAP 0 and 3 or varicose veins combine superficial vein thrombophlebitis, in comparison to the pre-treatment. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 53 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose

2015 Clinical Trials

175. Transdermal Patch CVD 1000: The Effect of Heat on Nicotine Release From Nicotine Patches in Adult Smokers

reactions not evaluable 17. Subject who currently has any of the following conditions: Thrombophlebitis, thromboembolic disorders A past history of deep vein thrombophlebitis or thromboembolic disorders Cerebrovascular or coronary artery disease (current or past history) Valvular heart disease with complications Severe hypertension Diabetes with vascular involvement Headaches with focal neurological symptoms Major surgery with prolonged immobilization 18. Medical history of a serious chronic condition (...) (e.g. allergic conditions such as anaphylaxis, asthma or generalized drug reaction). 19. Medical history of significant dermatologic diseases or conditions, such as atopy, psoriasis, vitiligo or conditions known to alter skin appearance or physiologic response (e.g. diabetes, porphyria). 20. History of significant dermatologic cancers (e.g. melanoma, squamous cell carcinoma), except basal cell carcinomas that were superficial and did not involve the investigative site. 21. Within 10 hours prior

2015 Clinical Trials

176. Evaluation of the Immune Restoration Potential Of Lenalidomide

testing as required in the Revlimid REMS® program. Exclusion Criteria: Progressive CLL requiring therapy based on 2008 international working group guidelines (iwCLL 2008, Hallek et al, Blood 2008). Pregnant or breast-feeding women will not be entered on this study due to risks of fetal and teratogenic adverse events as seen in animal/human studies. Known hypersensitivity to thalidomide or lenalidomide. Prior lenalidomide-associated deep vein thrombosis Deep vein thrombosis or superficial (...) thrombophlebitis of any cause on current anticoagulation therapy at the time of screening. Patients who are currently receiving another investigational agent are excluded. Patients who have had chemotherapy (e.g., purine analogues, alkylating agents), radiation therapy, tyrosine kinase inhibitor therapy, or participation in any investigational drug treatment within 4 weeks of initiation of lenalidomide or at any time during the study. Patients who have had prior (within 8 weeks of initiation of lenalidomide

2015 Clinical Trials

177. Lenalidomide and Obinutuzumab for Previously Untreated CLL

(if applicable), including development of erythema nodosum or a desquamating rash while taking thalidomide or similar drugs. Deep vein thrombosis or superficial thrombophlebitis of any cause on current anticoagulation therapy at the time of screening. Patients who are currently receiving another investigational agent are excluded. Current infection requiring parenteral antibiotics. Known seropositive for or active viral infection with human immunodeficiency virus (HIV); or known active infection

2015 Clinical Trials

178. Diagnosis of Mondor's Disease in the Emergency Department with Bedside Ultrasound (PubMed)

Diagnosis of Mondor's Disease in the Emergency Department with Bedside Ultrasound Mondor's disease is a rare condition characterized by a superficial thrombophlebitis that can occur in the thoracoabdominal and genital areas. Findings with ultrasound in penile Mondor's disease are readily measurable: a noncompressible penile vein without flow and absence of tears of the corpus cavernosum or tunica albuginea, hematoma, or evidence of fracture of the penis. We present a case of Mondor's disease

Full Text available with Trip Pro

2015 Case Reports in Emergency Medicine

179. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: A randomized, placebo-controlled, multiple-dose study. (PubMed)

anaphylactoid reaction and 1 had grade 2 superficial thrombophlebitis. Other adverse events were mild to moderate and included headache, fatigue, infusion site reactions, and urinary tract infection.PDA-001 infusions were safe and well tolerated in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis patients. No paradoxical worsening of lesion counts was noted with either dose.Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

Full Text available with Trip Pro

2015 Multiple sclerosis and related disorders Controlled trial quality: predicted high

180. Prophylaxis of Ileostomy Closure Site Hernia by Placing Mesh

independently. Respiratory complications [ Time Frame: 30 days after surgery ] Pneumonia, Atelectasis, Pulmonary embolism, Respiratory distress syndrome ... This is a Clinical measure always supported by image . All the morbidity problems are reported independently. Vascular Complications [ Time Frame: 30 days after surgery ] Deep venous thrombosis, phlebitis, thrombophlebitis, ... This is a Clinical measure supported by more specific test if necessary . All the morbidity problems are reported independently (...) disorientation. Local infection [ Time Frame: 30 days after surgery ] Superficial, deep, body-cavity This is a Clinical measure supported by image if necessary All the morbidity problems are reported independently Local complications [ Time Frame: 30 days after surgery ] Hematoma, seroma, evisceration This is a Clinical measure All the morbidity problems are reported independently Hospital stay [ Time Frame: Days ] Hospital stay since surgery is done Eligibility Criteria Go to Information from the National

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>